BioSpace News Archive

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the International Society of Nephrology World Congress of Nephrology (WCN).

Dermata Therapeutics, Inc. announced the closing of its previously announced public offering of 1,618,123 shares of the Company’s common stock and accompanying Series A warrants to purchase up to 1,618,123 shares of common stock and Series B warrants to purchase up to 1,618,123 shares of common stock at a combined offering price of $3.09 per share of common stock and accompanying warrants.

Karuna Therapeutics, Inc. announced that it has commenced an underwritten public offering of $400.0 million of its common stock.

Oxurion NV has announced the completion of Tranche 1 of funding under the Subscription agreement with Atlas Special Opportunities LLC.

The Centers for Medicare & Medicaid Services has awarded Dynanet a Prime contract to provide services under the Agile Collaboration and Modernization Endeavors Blanket Purchase Agreement.

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced two key publications.

Dyne Therapeutics, Inc today announced three poster presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 19-22, 2023, in Dallas, TX, and virtually.

Illumina today issued the following response to Carl Icahn’s public statements and letters to Illumina’s shareholders dated March 13 and March 15, 2023.

Dante Genomics , a global leader in genomics and precision medicine, launched today the beta version of Avanti, the Company’s proprietary B2B software for variant interpretation and report writing at scale.

Biopharmaceutical firm NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”), disclosed today additional results from an internal preclinical study of its investigational drug ExoPTEN demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries.